Houston, TX-based biotech Bellicum Pharmaceuticals gained a $5.7 million influx of cash to continue testing and manufacturing its cancer therapy, CaspaCIDe. The therapy is being tested for Graft versus Host Disease, a side effect that can occur from bone marrow transplants and is often fatal. Early results from trials show promising results that have reduced hematologic malignancies. The funding came from the Cancer Prevention and Research Institute of Texas. Bellicum release